Ranbaxy Laboratories declines on reporting consolidated net loss of Rs 185.92 crore in Q1FY15

30 Jul 2014 Evaluate

Ranbaxy Laboratories is currently trading at Rs. 586.95, down by 3.05 points or 0.52% from its previous closing of Rs. 590.00 on the BSE.

The scrip opened at Rs. 588.00 and has touched a high and low of Rs. 596.85 and Rs. 575.65 respectively. So far 178776 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 592.00 on 28-Jul-2014 and a 52 week low of Rs. 253.95 on 02-Aug-2013.

Last one week high and low of the scrip stood at Rs. 596.85 and Rs. 554.40 respectively. The current market cap of the company is Rs. 24900.18 crore.

The promoters holding in the company stood at 63.40% while Institutions and Non-Institutions held 20.53% and 13.65% respectively.

Ranbaxy Laboratories has reported net profit of Rs 755.12 crore for the quarter under review as compared to a net loss of Rs 608.80 crore for the quarter ended June 30, 2013. The company’s total income has increased by 49.96% to Rs 2204.39 crore for the quarter under review from Rs 1469.93 crore for the corresponding quarter of the previous year.

On the consolidated basis, the company has reported a net loss after taxes and Minority Interest and Share of Profit of Associates of Rs 185.92 crore for the quarter as compared to net loss of Rs 524.24 crore for the same quarter in the previous year. Besides, total income of the company has decreased by 8.16% at Rs 2451.70 crore for quarter under review as compared to Rs 2669.58 crore for the quarter ended June 30, 2013.

 

Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×